Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Scientists develop new method to create stem cells for human liver and pancreas

A new method for creating stem cells for the human liver and pancreas, which could enable both cell types to be grown in sufficient quantities for clinical use, has been developed by scientists.

11 Oct 2013

Researchers identify gene that orchestrates important branching of nerve fibers

Our ability to detect heat, touch, tickling and other sensations depends on our sensory nerves. Now, for the first time, researchers at Albert Einstein College of Medicine of Yeshiva University have identified a gene that orchestrates the crucially important branching of nerve fibers that occurs during development. The findings were published online today in the journal Cell.

11 Oct 2013

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association.

11 Oct 2013

Intravenous feeding can cause liver damage, say researchers

Researchers know that feeding some patients intravenously can save their lives - but also can cause liver damage. Now scientists at the University of Colorado and Children's Hospital Colorado have figured out the likely culprit, one of the ingredients in intravenous food, behind the liver problems.

10 Oct 2013

Risk of dying from invasive breast cancer lower among multivitamin/mineral users

Findings from a study involving thousands of postmenopausal women suggest that women who develop invasive breast cancer may benefit from taking supplements containing both multivitamins and minerals.

9 Oct 2013

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc.

9 Oct 2013

Retinitis pigmentosa test identifies mutation found in Ashkenazi Jewish population

You might not think to look to a urine test to diagnose an eye disease. But a new Duke University study says it can link what is in a patient's urine to gene mutations that cause retinitis pigmentosa, or RP, an inherited, degenerative disease that results in severe vision impairment and often blindness. The findings appear online in the Journal of Lipid Research.

9 Oct 2013

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP).

9 Oct 2013

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.

8 Oct 2013

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

...

8 Oct 2013

New injection device delivers optimum treatment dose to hepatitis C patients

A new injection device, ViraferonPeg Clearclick, has launched in the UK today for hepatitis C patients to accurately titrate and self-administer their weekly dose of ViraferonPeg (peginterferon alfa-2b).

5 Oct 2013

Viewpoints: Marketplaces offer Americans the kind of shopping they like; enrollment isn't as robust as administration claims

Americans have grown accustomed to online comparison shopping, as the overwhelming number who clicked on health-exchange websites demonstrates.

5 Oct 2013

FDA approves Clinolipid injectable emulsion for intravenous feeding in adult patients

The U.S. Food and Drug Administration today approved Clinolipid (lipid injectable emulsion, USP) for intravenous feeding (parenteral nutrition) in adult patients, providing a source of calories and essential fatty acids for adult patients who are unable to eat or drink. Clinolipid was granted a priority review to help alleviate a drug shortage.

5 Oct 2013

Substance abuse treatment before, after liver transplantation has lower alcohol relapse rates

New research reports that liver transplant recipients who receive substance abuse treatment before and after transplantation have much lower alcohol relapse rates than those untreated or only treated prior to transplantation.

4 Oct 2013

Saint Luke's liver transplantation program receives CMS certification

The liver transplantation program at Saint Luke's Hospital of Kansas City has received certification by the Centers for Medicare and Medicaid. The certification is an important step in enhancing the hospital's ability to care for Medicare-covered patients suffering from end-stage liver disease, and attract other insurers who base their coverage on the CMS certification.

2 Oct 2013

Researchers develop renal risk index to predict post-transplant end-stage renal disease

End-stage renal disease is one of the major public health problems among solid organ transplant recipients that is associated with death after transplant and high cost of care.

2 Oct 2013

Genetic study helps identify obese diabetes patients who are at risk of developing NAFLD

A groundbreaking study of nearly 2,300 extremely obese diabetes patients, led by the Translational Genomics Research Institute, has identified genes associated with unhealthy liver function.

2 Oct 2013

Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting

New data from Boehringer Ingelheim's hepatitis C virus clinical development program have been accepted for presentation at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 1-5 in Washington, D.C.

1 Oct 2013

Canada should start screening 'Baby Boomers' for hepatitis C virus infection, say liver specialists

Canada should begin screening 'Baby Boomers' for the hepatitis C virus infection, since this age group is likely the largest group to have the illness, and most don't know they have it, say a group of liver specialists in the Toronto Western Hospital Francis Family Liver Clinic. Unlike many other chronic viral infections, early treatment makes hepatitis C curable.

1 Oct 2013

Lumena Pharmaceuticals initiates LUM001 clinical program in children with ALGS

Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the initiation of a global clinical program to evaluate its drug candidate LUM001 in children with Alagille syndrome. The first patient has been dosed in the IMAGO Phase II study being conducted in the U.K., and enrollment of pediatric patients is expected to begin later this year in the ITCH Phase II study in the U.S.

26 Sep 2013

Liver Disease News and Research

Further Reading

Scientists develop new method to create stem cells for human liver and pancreas

Researchers identify gene that orchestrates important branching of nerve fibers

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

Intravenous feeding can cause liver damage, say researchers

Risk of dying from invasive breast cancer lower among multivitamin/mineral users

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Retinitis pigmentosa test identifies mutation found in Ashkenazi Jewish population

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

New injection device delivers optimum treatment dose to hepatitis C patients

Viewpoints: Marketplaces offer Americans the kind of shopping they like; enrollment isn't as robust as administration claims

FDA approves Clinolipid injectable emulsion for intravenous feeding in adult patients

Substance abuse treatment before, after liver transplantation has lower alcohol relapse rates

Saint Luke's liver transplantation program receives CMS certification

Researchers develop renal risk index to predict post-transplant end-stage renal disease

Genetic study helps identify obese diabetes patients who are at risk of developing NAFLD

Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting

Canada should start screening 'Baby Boomers' for hepatitis C virus infection, say liver specialists

Lumena Pharmaceuticals initiates LUM001 clinical program in children with ALGS

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News